Clinical, Medical & Diagnostic Products
The quiet importance of UN3373 – Biological Substances, Category B
In the vast networks of global logistics, one small label plays a vital role in public health and medical progress: UN3373. Designating ‘Biological Substances, Category B’ to a package might appear mundane to the untrained eye, but it is critical to the safe and efficient transport of human or animal specimens for medical diagnostics and research.
UN3373 applies to substances that are known or suspected to contain pathogens. These might include blood, urine, faeces or tissue samples used in routine diagnostics, clinical trials, or disease surveillance. What makes UN3373 unique is its balance; it imposes essential safety protocols without the stricter requirements of Category A (more dangerous infectious materials), enabling both practicality and protection.
Despite its seeming simplicity, this label is tightly regulated. Packaging must follow a triple-layered system: a leak-proof primary receptacle, a durable secondary container that contains sufficient absorbent material (for liquid samples) in case of leakage, and outer packaging containing the important UN3373, Category B labelling. This system ensures the safety of handlers and the integrity of the sample.
In an era of rising diagnostic testing, from early detection cancer screening to at-home sample collection, the role of UN3373 cannot be overstated. It allows hospitals, laboratories, and research institutions to move samples quickly and compliantly. Mistakes in packaging or labelling can lead to shipment delays, legal penalties, or worse, compromised diagnostics.
UN3373 is not just a code; it’s vital within modern medicine. Respecting it means safeguarding not just samples, but the systems of care and innovation that depend on them.
Alpha Laboratories provides a wide range of UN3373, Category B sample packaging materials that help make your regulatory compliance convenient, consistent and cost-effective.
For further details visit
ilmt.co/PL/B21N More information online:
ilmt.co/PL/Kwxw
Transforming urinalysis: Faster, smarter, more precise
HUMAN Diagnostics has successfully relaunched its urinalysis portfolio, introducing cutting-edge solutions that enhance precision, efficiency, and accessibility in diagnostic testing. The updated portfolio features innovative technologies designed to streamline urinalysis in diverse healthcare settings.
At the heart of this transformation are two key advancements: the HumaCombilyzer, a portable, semi-automated urine strip analyser, and the HumaVision, a state-of-the-art automated urine particle analyser powered by artificial intelligence (AI) and Digital Holographic Microscopy (DHM). These innovations ensure faster and more accurate diagnostics, improving workflows and patient outcomes worldwide.
“Urinalysis is a fundamental diagnostic tool, and with our restructured portfolio, HUMAN is setting a new standard for efficiency and accuracy in this vital field,” said Dr Christine Hettmann-Dreuw, VP Marketing & Strategic Purchase at HUMAN Diagnostics. “By integrating advanced AI and user-friendly designs, we are enhancing workflows while maintaining our commitment to providing solutions that are accessible worldwide.”
The HumaCombilyzer is a versatile urine test strip analyser capable of delivering rapid results for up to 14 parameters. Designed for small clinics and mobile healthcare environments, its portability and intuitive interface make it particularly suited for resource-limited settings. Meanwhile, the HumaVision is the smallest, most user-friendly urine microscope on the market. Utilising DHM and AI, it delivers precise and fully digitalised urine particle analysis in just 3–7 minutes, eliminating the need for complex sample preparation. Compared to manual microscopy, it offers a larger field of view and more reliable results.
The updated portfolio is designed to support the diagnosis of urinary tract infections, kidney conditions, and metabolic disorders such as diabetes and liver diseases. By automating key processes, these instruments significantly reduce human error, optimise laboratory workflows, and enhance diagnostic confidence.
At Medlab ME 2025, attendees had the opportunity to experience HUMAN Diagnostics’ innovations firsthand. Live demonstrations at the HUMAN booth highlighted the practical benefits of these solutions, reinforcing their impact on improving diagnostic workflows and patient care on a global scale.
HUMAN Diagnostics remains committed to supporting healthcare professionals in over 160 countries with high-quality, German-engineered solutions that enhance equitable access to life-saving diagnostics.
More information online:
ilmt.co/PL/MKe0 Sixth-generation test transforms emergency heart attack diagnosis
Roche has announced results from the TSIX Study Program, showing that its sixth-generation high-sensitivity Troponin T test delivers unprecedented accuracy in diagnosing heart attacks. Recently granted CE Mark, the Elecsys® Troponin T hs Gen 6 test allows clinicians to quickly identify acute myocardial infarction (AMI) while ruling out non-cardiac causes, ensuring patients receive timely care.
The TSIX program involved over 13,000 participants across the US, China, Japan, and Europe, validating the test in real-world clinical settings. Study results presented at the European Society for Emergency Medicine and the European Society of Cardiology conferences demonstrated that the test accurately detects AMI and identifies patients who do not have a heart attack, supporting rapid and efficient triage in emergency departments. Chest pain is one of the most common reasons for emergency visits, yet only a small proportion of patients are experiencing a heart attack. With emergency departments often facing overcrowding, the ability to quickly and reliably identify those in need of urgent care is critical for patient outcomes and effective use of resources.
“Coronary artery disease continues to place immense strain on healthcare systems, particularly in emergency care,” said Matt Sause, CEO of Roche Diagnostics. “Our new test detects even minimal elevations in troponin levels, a key biomarker of heart attack, giving clinicians the confidence to act quickly. Every second counts, and this test ensures patients receive life-saving care without delay, while resources can be prioritised effectively.”
Roche has a 30-year legacy in troponin innovation, having introduced the first high-sensitivity troponin tests and the first FDA-approved assay. The sixth-generation test represents the next step in managing coronary artery disease, combining precise biomarker measurement with a growing portfolio of assays and digital solutions that support both laboratory and near-patient diagnostics. The TSIX Study Program confirms that the Elecsys® Troponin T hs Gen 6 test delivers fast, reliable, and accurate results, enabling emergency clinicians to make informed decisions and improving outcomes for patients with suspected heart attacks.
More information online:
ilmt.co/PL/Mv3D 65873pr@reply-direct.com
64335pr@reply-direct.com
64878pr@reply-direct.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64
